Biologist & Life Scientist jobs

Postdoctoral Fellow-MSH

Mount Sinai Health SystemUnited StatesPhD

Pay not listed

2 things to check before you apply.

On Mount Sinai Health System’s own careers site (Oracle Recruiting), checked open today.

  • To check: Posted by the employer 5 years agoLong-open jobs are sometimes already filled. Ask when they plan to hire.
  • To check: No pay range listedAsk for the pay range before you interview.
  • Checked: On the company's own careers siteOracle Recruiting board
  • Checked: Checked open todayOracle Recruiting board
  • Checked: No reposts foundOracle Recruiting board
  • Trust score 60 / 100 · Check details
See all 6 checksShow fewer
How we check

What you’ll do

  • Investigate the molecular basis of synthetic lethality between PRMT inhibition and MYC overexpression or splicing-factor mutations.
  • Study how PRMT inhibition affects spliceosomal assembly and splicing fidelity in cancer cells.

Summarised from the posting by AI and can be wrong. The full description is the source.

Requirements

Experience

  • Strong background in cancer, RNA biology, and chromatin biology
  • Familiarity with recent advances in cancer, RNA, and chromatin biology
  • Strong background in mouse models of cancer, molecular biology, and RNA biology (preferred)

Education

  • Ph.D. in molecular biology or a similar field

Skills

  • Familiarity with NGS technologies

Your match

Sign in and add your resume to see which of this job's requirements it shows.

Sign in to check your match

Saved to your account, encrypted. The AI that reads it doesn't keep it or train on it.

Full job description

From Mount Sinai Health System’s careers site

Roles & Responsibilities:

  • Our group has recently identified that inhibiting spliceosomal assembly through inhibition of arginine methylation provides an effective means of therapeutic splicing inhibition. Specifically, inhibiting either symmetric arginine methylation (mediated by the protein arginine methyltransferase 5 -PRMT5) or asymmetric dimethyl arginine methylation (mediated by type I PRMTs (PRMT1, 3, 4, and 6)) reduces splicing fidelity resulting in strong preferential killing of (i) splicing factor-mutant leukemias and (ii) MYC-overexpressing lymphomas over their wildtype counterparts.
Show full descriptionShow less

In follow-up projects ongoing in the lab we aim to determine the molecular basis for the synthetic lethality between PRMT inhibition and either MYC overexpression or SF mutations. The significance of these studies is that inhibitors of PRMTs are now entering phase I clinical trials in patients with a variety of cancer types and defining the mechanistic effects and therapeutic utility of PRMT inhibitors for specific genetic subsets of cancers may have incredible therapeutic importance. The health relatedness is that our studies may identify new therapeutic opportunities for a variety of cancer types that have no curative therapies for the majority of patients with these diseases.

Requirements:

  • Strong background in Mouse models of cancer, Molecular Biology and RNA biology is appreciated.
  • Ph.D. degree in molecular biology or similar. Strong background in cancer, RNA/chromatin biology and familiarity with recent advances in these fields and NGS technologies. Excellent communication and teaching skills. Must be able to work as an individual while part of a small team.

.

.

Something wrong with this job? Report it · This flag looks wrong

Similar jobs

See more like this